Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Publication|Articles|October 19, 2026
- October 2026
- Volume 92
- Issue 10
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
Author(s)Ned Milenkovich, PharmD, JD
Fact checked by: Yasmeen Qahwash
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Advertisement
Advertisement
If you work anywhere near compounding, wellness, sports medicine, or longevity medicine, you have probably heard the names by now: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Peptides have gone mainstream—or at least much closer to it.
Related to this article
Pharmacists make a difference in patients’ lives through MTM services.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
Advertisement
Advertisement